US LNG exports surge but will buyers in China turn up?
Cantor Fitzgerald reiterated its Overweight rating and $13.00 price target on Taysha Gene Therapies (NASDAQ:TSHA) stock Friday, suggesting significant upside from the current price of $2.65. With a market capitalization of $569 million, InvestingPro data shows the stock is currently trading above its Fair Value. The research firm maintained its positive outlook on the gene therapy company ahead of expected trial details.
The firm noted that caregivers prioritize three potential therapy outcomes: hand use, verbal language, and walking abilities. These three domains align with what Taysha Gene Therapies will be evaluating in its upcoming pivotal trial. The company has demonstrated strong momentum, with a 28% price return over the past six months, while maintaining a healthy balance sheet with more cash than debt.
Cantor Fitzgerald highlighted that seizures, sleep dysfunction, and gastrointestinal dysfunction were also identified as important measures for caregivers. The research firm emphasized that these priorities match the focus areas of Taysha’s clinical program.
The company is expected to disclose details of its NGNE registrational trial later this month. This pivotal study represents a significant milestone in Taysha’s clinical development program.
Cantor Fitzgerald’s analysis pointed to positive efficacy data already demonstrated by both Taysha and NGNE across the priority domains identified by caregivers. The maintained price target reflects the firm’s continued confidence in Taysha’s therapeutic approach. InvestingPro subscribers have access to 10 additional investment tips for TSHA, along with comprehensive financial analysis and Fair Value calculations in the Pro Research Report, helping investors make more informed decisions about this emerging biotech company.
In other recent news, Taysha Gene Therapies has been actively advancing its gene therapy program for Rett syndrome. The company reported positive Phase 1/2 data for its AAV-based gene therapy, TSHA-102, which has garnered significant attention at recent scientific meetings. This progress has led Cantor Fitzgerald to maintain its Overweight rating with a $13 price target, citing strong positive sentiment from stakeholders. Additionally, Canaccord Genuity analysts have raised their price target to $11, reflecting increased confidence in the therapy’s success and a recent $200 million offering to support ongoing projects.
Taysha also announced an increase in authorized shares from 400 million to 700 million following stockholder approval. This move aligns with the company’s strategic initiatives to support its development pipeline. Furthermore, Taysha has been preparing for upcoming presentations at the International Rett Syndrome Foundation Scientific Meeting, where it will share data on safety, efficacy, and caregiver insights. Cantor Fitzgerald reiterated its Overweight rating with a $7 price target, highlighting the promising new data and the outlined regulatory pathway for TSHA-102. These developments underscore Taysha’s continued efforts to advance treatments for unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.